An epidemiological overview of the relationship between hormone replacement therapy and breast cancer

Expert Review of Endocrinology and Metabolism

Volumn 6, Issue 3, 2011, Pages 397-409

  Salagame, Usha ^a   Canfell, Karen ^a   Banks, Emily ^b  

^a CANCER RESEARCH DIVISION   (Australia)

^b The Australian National University   (Australia)

Author keywords

combined estrogen progestin therapy; estrogen; hormone replacement therapy; medroxyprogesterone acetate; progestins

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR; GESTAGEN;

BODY MASS; BREAST CANCER; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER RISK; CANCER SCREENING; DRUG FORMULATION; HISTOPATHOLOGY; HUMAN; MAMMOGRAPHY; MENOPAUSE; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SENSITIVITY AND SPECIFICITY; TREATMENT DURATION;

EID: 79956113341     PISSN: 17446651     EISSN: 17448417     Source Type: Journal    
DOI: 10.1586/eem.11.31     Document Type: Review

References (78)

1. Vandenbroucke JP. When are observational studies as credible as randomised trials? Lancet 363(9422), 1728-1731 (2004). (Pubitemid 38670333)
2. Key TJ, Verkasalo PK, Banks E. The epidemiology of breast cancer. Lancet Oncol. 2, 133-140 (2001).
3. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 350(9084), 1047-1059 (1997).
4. Writing group for the Women's Health Initiative investigators. Risks and benefits of estrogen plus progestin in healthy menopausal women: principal results from the Women's Health Initiative randomised controlled trial. JAMA 288, 321-333 (2002).
5. Prentice RL, Manson JE, Langer RD, et al. Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. Am. J. Epidemiol. 170(1), 12-23 (2009).
6. Beral V; Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362(9382), 419-427 (2003). (Pubitemid 36999703)
7. Reeves G, Beral V, Green J, Gathani T, Bull D; for the Million Women Study collaborators. Hormonal therapy for menopause and breast-cancer risk by histological type: a cohort study and meta-analysis. Lancet Oncol. 7(11), 910-918 (2006). (Pubitemid 44615945)
8. Beral V, Reeves G, Bull D, Green J; for the Million Women Study collaborators. Breast cancer risk in relation to the interval between menopause and starting hormone therapy. J. Natl Cancer Inst. 103, 1-10 (2011).
9. Canfell K, Banks E, Moa AM, Beral V. Decrease in breast cancer incidence following a rapid fall in use of hormone replacement therapy in Australia. Med. J. Aust. 188(11), 641-644 (2008).
10. Canfell K, Banks E, Clements M, et al. Sustained lower rates of HRT prescribing and breast cancer incidence in Australia since 2003. Breast Cancer Res. Treat. 117(3), 671-673 (2009).
11. Lambe M, Wigertz A, Holmqvist M, et al. Reductions in use of hormone replacement therapy: effects on Swedish breast cancer incidence trends only seen after several years. Breast Cancer Res. Treat. 121, 679-683 (2010).
12. De P, Neutel CI, Olivotto I, Morrison H. Breast cancer incidence and hormone replacement therapy in Canada. J. Natl Cancer Inst. 102, 1489-1495 (2010).
13. Katalinic A, Rawal R. Decline in breast cancer incidence after decrease in utilisation of hormone replacement therapy. Breast Cancer Res. Treat. 107(3), 427-430 (2008). (Pubitemid 351172118)
14. Katalinic A, Lemmer A, Zawinell A, Rawal R, Waldmann A. Trends in hormone therapy and breast cancer incidence -results from the German Network of Cancer Registries. Pathobiology 76(2), 90-97 (2009).
15. Ravdin PM, Cronin KA, Howlader N, et al. The decrease in breast-cancer incidence in the United States. N. Engl. J. Med. 356(16), 1670-1674 (2007). (Pubitemid 46631679)
16. Chlebowski RT, Anderson GL, Gass M, et al. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 304(15), 1684-1692 (2010).
17. Marshall SF, Clarke CA, Deapen D, et al. Recent breast cancer incidence trends according to hormone therapy use: the California Teachers Study cohort. Breast Cancer Res. 12(1), R4 (2010).
18. Banks E, Canfell K. Recent declines in breast cancer incidence: mounting evidence that reduced use of menopausal hormones is largely responsible. Breast Cancer Res. 12(1), 103 (2010).
19. The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291(14), 1701-1712 (2004).
20. Heiss G, Wallace R, Anderson GL, et al. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA 299(9), 1036-1045 (2008). (Pubitemid 351347060)
21. Chlebowski RT, Hendrix SL, Langer RD, et al. The Women's Health Initiative randomized trial and mammography in healthy postmenopausal women: influence of estrogen plus progestin on breast cancer. JAMA 289(24), 3243-3253 (2003). (Pubitemid 37430077)
22. Colditz GA. Estrogen, estrogen plus progestin therapy, and risk of breast cancer. Clin. Cancer Res. 11, S909-S917 (2005).
23. Prentice RL, Chlebowski RT, Stefanick ML, et al. Estrogen plus progestin therapy and breast cancer in recently postmenopausal women. Am. J. Epidemiol. 167(10), 1207-1216 (2008). (Pubitemid 351670642)
24. Anderson GL, Chlebowski RT, Rossouw JE, et al. Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin. Maturitas 55(2), 103-115 (2006). (Pubitemid 44307491)
25. Collaborative Group on Hormonal Factors in Breast Cancer. Alcohol, tobacco and breast cancer: collaborative reanalysis of individual data from 53 epidemiological studies, including 58515 women with breast cancer and 95067 women without the disease. Br. J. Cancer 87, 1234-1245 (2002).
26. Reeves G, Pirie K, Beral V, Green J, Spencer E; For the Million Women Study collaborators. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. Br. Med. J. 335, 1134-1139 (2007). (Pubitemid 350247286)
27. Collaborative Group on Hormonal Factors in Breast Cancer. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58209 women with breast cancer and 101986 women without the disease. Lancet 358, 1389-1399 (2001).
28. Food and Drug Administration, US Department of Health and Human Services. Menopause & Hormones. US Food and Drug Administration, Rockville, MD, USA (2005).
29. Chlebowski RT, Kuller LH, Prentice RL, et al. Breast cancer after use of estrogen plus progestin in postmenopausal women. N. Engl. J. Med. 360(6), 573-587 (2009).
30. Kumle M. Declining breast cancer incidence and decreased HRT use. Lancet 372, 608-610 (2008).
31. Barrett-Connor E. Hormones and heart disease in women: the timing hypothesis Am. J. Epidemiol. 166(5), 506-510 (2007). (Pubitemid 47283648)
32. Rossouw JE, Prentice RL, Manson JE. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 297(13), 1465-1477 (2007). (Pubitemid 46556472)
33. Manson JE, Bassuk SS. Invited commentary: hormone therapy and risk of coronary heart disease -why renew the focus on the early years of menopause? Am. J. Epidemiol. 166(5), 511-517 (2007). (Pubitemid 47283647)
34. Prentice RL, Chlebowski RT, Stefanick ML, et al. Conjugated equine estrogens and breast cancer risk in the Women's Health Initiative clinical trial and observational study. Am. J. Epidemiol. 167(12), 1407-1415 (2008).
35. Banks E, Canfell K. Invited commentary: hormone therapy risks and benefits -the Women's Health Initiative findings and the postmenopausal estrogen timing hypothesis. Am. J. Epidemiol. 170(1), 24-28 (2009).
36. Burger H. WHI risks: any relevance to menopause management? Maturitas 57(1), 6-10 (2007). (Pubitemid 46602881)
37. Wren B. The benefits of oestrogen following menopause: Why hormone replacement therapy should be offered to postmenopausal women. Med. J. Aust. 190(6), 321-325 (2009).
38. Lee S, Kolonel L, Wilkens L, Wan P, Henderson B, Pike M. Postmenopausal hormone therapy and breast cancer risk: the Multiethnic Cohort. Int. J. Cancer 118(5), 1285-1291 (2006). (Pubitemid 43185619)
39. Lee SA, Ross RK, Pike MC. An overview of menopausal oestrogen-progestin hormone therapy and breast cancer risk. Br. J. Cancer 92(11), 2049-2058 (2005). (Pubitemid 40897429)
40. Stefanick ML, Anderson GL, Margolis KL, et al.; for the WHI Investigators. Effects of Conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 295(14), 1647-1657 (2006).
41. Chlebowski RT, Anderson G, Pettinger M, et al. Estrogen plus progestin and breast cancer detection by means of mammography and breast biopsy. Arch. Int. Med. 168(4), 370-377 (2008). (Pubitemid 351347128)
42. Banks E, Reeves G, Beral V, et al. Hormone replacement therapy and false positive recall in the Million Women Study: patterns of use, hormonal constituents and consistency of effect. Breast Cancer Res. 8(1), R8 (2006).
43. Banks E. Hormone replacement therapy and the sensitivity and specificity of breast cancer screening: a review. J. Med. Screen 8, 29-35 (2001). (Pubitemid 32467573)
44. Banks E, Reeves G, Beral V, et al. Influence of personal characteristics of individual women on the sensitivity and specificity of mammography in the Million Women Study: cohort study. Br. Med. J. 329, 477-480 (2004).
45. Banks E, Reeves G, Beral V, et al. Impact of use of hormone replacement therapy on false positive recall in the NHSBSP: results from the Million Women Study. Br. Med. J. 328, 1291-1292 (2004). (Pubitemid 38703488)
46. Verkooijen HM, Fioretta G, Vlastos G, et al. Important increase of invasive lobular breast cancer incidence in Geneva, Switzerland. Int. J. Cancer 104(6), 778-781 (2003). (Pubitemid 36418517)
47. Fournier A, Fabre A, Mesrine S, et al. Use of different postmenopausal hormone therapies and risk of histology-and hormone receptor-defined invasive breast cancer. J. Clin. Oncol. 26(8), 1260-1268 (2008).
48. Collins JA, Blake JM, Crosignani PG. Breast cancer risk with postmenopausal hormonal treatment. Hum. Reprod. Update 11(6), 545-560 (2005). (Pubitemid 41631306)
49. Phipps AI, Li CI, Kerlikowske K, Barlow WE, Buist DSM. Risk factors for ductal, lobular, and mixed ductal-lobular breast cancer in a screening population. Cancer Epidemiol. Biomarkers Prev. 19(6), 1643-1654 (2010).
50. Calle EE, Feigelson HS, Hildebrand JS, Teras LR, Thun MJ, Rodriguez C. Postmenopausal hormone use and breast cancer associations differ by hormone regimen and histologic subtype. Cancer 115, 936-945 (2009).
51. Glass AG, Lacey JV, Carreon JD, Hoover RN. Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J. Natl Cancer Inst. 99(15), 1152-1161 (2007). (Pubitemid 47233065)
52. Kerlikowske K, Miglioretti DL, Buist DSM, Walker R, Carney PA. Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population. J. Natl Cancer Inst. 99(17), 1335-1339 (2007). (Pubitemid 47394172)
53. Clarke CA, Glaser SL. Declines in breast cancer after the WHI: apparent impact of hormone therapy. Cancer Causes Control 18, 847-852 (2007). (Pubitemid 47125116)
54. Parkin DM. Is the recent fall in incidence of post-menopausal breast cancer in UK related to changes in use of hormone replacement therapy? Eur. J. Cancer 45, 1649-1653 (2009).
55. Seradour B, Allemand H, Weill A, Ricordeau P. Changes by age in breast cancer incidence, mammography screening and hormone therapy use in France from to 2006. Bull Cancer 96(4), E1-E6 (2009).
56. Ponti A, Rosso S, Zanetti R, Ricceri F, Tomatis M, Segnan N. Re: Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J. Natl Cancer Inst. 99(23), 1817-1818 (2007). (Pubitemid 351767205)
57. Soerjomataram I, Coebergh JW, Louwman MW, Visser O, Van Leeuwen FE. Does the decrease in hormone replacement therapy also affect breast cancer risk in The Netherlands? J. Clin. Oncol. 25, 5038-5039 (2007). (Pubitemid 350220443)
58. Cronin KA, Ravdin PM, Edwards BK. Sustained lower rates of breast cancer in the United States. Breast Cancer Res. Treat. 117(1), 223-224 (2009).
59. Clarke CA, Robbins AS. In reply. Does the decrease in hormone replacement therapy also affect breast cancer risk in The Netherlands [letter]? J. Clin. Oncol. 25, 5039-5040 (2007).
60. Fernandez SV, Russo J. Estrogen and xenoestrogens in breast cancer. Toxicol. Pathol. 38(1), 110-122 (2010).
61. Tan H, Zhong Y, Pan Z. Autocrine regulation of cell proliferation by estrogen receptor-a in estrogen receptor-a-positive breast cancer cell lines. BMC Cancer 9, 31 (2009).
62. Eigeliene N, Harkonen P, Erkkola R. Effects of estradiol and medroxyprogesterone acetate on expression of the cell cycle proteins cyclin D1, p21 and p27 in cultured human breast tissues. Cell Cycle 7(1), 71-80 (2008).
63. Capuco AV, Ellis S, Wood DL, Akers RM, Garrett W. Postnatal mammary ductal growth: three-dimensional imaging of cell proliferation, effects of estrogen treatment, and expression of steroid receptors in prepubertal calves. Tissue Cell 34(3), 143-154 (2002).
64. Santen RJ. Risk of breast cancer with progestins: critical assessment of current data. Steroids 68(10-13), 953-964 (2003). (Pubitemid 37532420)
65. Kariagina A, Aupperlee MD, Haslam SZ. Progesterone receptor isoforms and proliferation in the rat mammary gland during development. Endocrinology 148(6), 2723-2736 (2007). (Pubitemid 46984816)
66. Graham JD, Mote PA, Salagame U, et al. DNA replication licensing and progenitor numbers are increased by progesterone in normal human breast. Endocrinology 150(7), 3318-3326 (2009).
67. Asselin-Labat ML, Vaillant F, Sheridan JM, et al. Control of mammary stem cell function by steroid hormone signalling. Nature 465(7299), 798-802 (2010).
68. Joshi PA, Jackson HW, Beristain AG, et al. Progesterone induces adult mammary stem cell expansion. Nature 465(7299), 803-807 (2010).
69. Jerry DJ, Dunphy KA, Hagen MJ. Estrogens, regulation of p53 and breast cancer risk: a balancing act. Cell Mol. Life Sci. 67(7), 1017-1023 (2010).
70. Travis RC, Reeves GK, Green J, et al.; for the Million Women Study Collaborators. Gene-environment interactions in women with breast cancer: prospective evidence from the Million Women Study. Lancet 375(9732), 2143-2151 (2010).
71. Beral V, Reeves GK, Banks E. Current evidence about the effect of hormone replacement therapy on the incidence of major conditions in postmenopausal women. Br. J. Obstet. Gynaecol. 111, 1-4 (2004).
72. Medicines and Healthcare Products Regulatory Agency UK. Hormone replacement therapy (HRT) -latest data from the Million Women Study and Women's Health Initiative Trial: MHRA Statement www.mhra.gov.uk/home/groups/pl-p/ documents/websiteresources/con 2032228.pdf (Accessed 11 March 2011)
73. Further advice on safety of hormone replacement therapy (HRT): no longer recommended as first choice for prevention of osteoporosis. www.hma.eu/uploads/ media/3.dez.2003.pdf (Accessed 11 March 2011)
74. US FDA. FDA Updates Hormone Therapy Information for Post Menopausal Women www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2004/ucm 108243.htm (Accessed 11 March 2011)
75. US FDA. Noncontraceptive estrogen drug products for the treatment of vasomotor symptoms and vulvar and vaginal atrophy symptoms-recommended prescribing information for health care providers and patient labeling www.fda.gov/downloads/Drugs/DrugSafety/InformationbyDrugClass/UCM135336.pdf (Accessed 11 March 2011)
76. Australian Drug Evaluation Committee. ADEC Summary Statement on HRT. Canberra, Australia: Therapeutic Goods Administration, Australian Government Department of Health and Ageing www.tga.gov.au/docs/html/hrtadec3.htm (Accessed 11 March 2011)
77. WHO Global Infobase https://apps.who.int/infobase/Comparisons.aspx (Accessed 11 March 2011)
78. National Cancer Institute; Surveillance Epidemiology and End Results (SEER) -Cancer Incidence rates http://seer.cancer.gov/statistics/types/ incidence.html (Accessed 11 March 2011)